Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Subscribe To Our Newsletter & Stay Updated